Evista

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
07-06-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
07-06-2022
Public Assessment Report Public Assessment Report (PAR)
31-03-2009

Active ingredient:

ралоксифен хидрохлорид

Available from:

Substipharm

ATC code:

G03XC01

INN (International Name):

raloxifene

Therapeutic group:

Полови хормони и слиза на половата система,

Therapeutic area:

Остеопороза, постменопауза

Therapeutic indications:

Evista е показан за лечение и профилактика на остеопороза при жени след менопауза. Наблюдавано е значително намаляване на честотата на фрактури на гръбначния стълб, но не и бедрената кост. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Product summary:

Revision: 30

Authorization status:

упълномощен

Authorization date:

1998-08-05

Patient Information leaflet

                                - 25 -
Б. ЛИСТОВКА
- 26 -
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
EVISTA 60 MG ФИЛМИРАНИ ТАБЛЕТКИ
ралоксифен хидрохлорид (raloxifene hydrochloride)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ
КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
•
Запазете тази листовка. Може да се
наложи да я прочетете отново.
•
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
•
Това лекарство е предписано
единствено и лично на Вас. Не го
преотстъпвайте на други
хора. То може да им навреди,
независимо, че признаците на тяхното
заболяване са същите
като Вашите.
•
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази листовка.
Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Evista и за какво се
използва
2.
Какво трябва да знаете, преди да
приемете Evista
3.
Как да приемате Evista
4.
Възможни нежелани реакции
5.
Как да съхранявате Evista
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА EVISTA И ЗА КАКВО СЕ
ИЗПОЛЗВА
Evista съдържа активно вещество
ралоксифен хидрохлорид.
Evista
                                
                                Read the complete document

Summary of Product characteristics

                                - 1 -
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
- 2 -
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Evista 60 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка филмирана таблетка съдържа 60 mg
ралоксифен хидрохлорид (raloxifene
hydrochloride),
еквивалентен на 56 mg ралоксифен
свободна база.
Помощни вещества с известно действие:
Всяка таблетка съдържа лактоза (149,40 mg)
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка
Елипсовидни, бели таблетки.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Evista е показана за лечение и
профилактика на остеопорозата при
жени в постменопауза.
Установено е значимо намаляване на
честотата на вертебралните, но не и на
тазовите фрактури.
При определяне на средството на избор
между Evista или друга терапия,
включително с естрогени,
при всяка конкретна жена в
постменопауза трябва да се вземат
пред вид симптомите, по време на
менопаузата, ефектът върху тъканите
на матката и млечните жлези и
сърдечносъдовият риск и
полза (вж. точка 5.1).
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
ДОЗИРОВКА
Препоръчителната доза е една таблетка
дневно, приложена перорално, като може
да се приема по
в
                                
                                Read the complete document

Similar products

Active ingredient ралоксифен хидрохлорид

ралоксифен хидрохлорид

ATC code G03XC01

G03XC01

Marketed by Substipharm

Substipharm

INN (International Name) raloxifene

raloxifene

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 07-06-2022
Summary of Product characteristics Summary of Product characteristics Spanish 07-06-2022
Public Assessment Report Public Assessment Report Spanish 31-03-2009
Patient Information leaflet Patient Information leaflet Czech 07-06-2022
Summary of Product characteristics Summary of Product characteristics Czech 07-06-2022
Public Assessment Report Public Assessment Report Czech 31-03-2009
Patient Information leaflet Patient Information leaflet Danish 07-06-2022
Summary of Product characteristics Summary of Product characteristics Danish 07-06-2022
Public Assessment Report Public Assessment Report Danish 31-03-2009
Patient Information leaflet Patient Information leaflet German 07-06-2022
Summary of Product characteristics Summary of Product characteristics German 07-06-2022
Public Assessment Report Public Assessment Report German 31-03-2009
Patient Information leaflet Patient Information leaflet Estonian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Estonian 07-06-2022
Public Assessment Report Public Assessment Report Estonian 31-03-2009
Patient Information leaflet Patient Information leaflet Greek 07-06-2022
Summary of Product characteristics Summary of Product characteristics Greek 07-06-2022
Public Assessment Report Public Assessment Report Greek 31-03-2009
Patient Information leaflet Patient Information leaflet English 07-06-2022
Summary of Product characteristics Summary of Product characteristics English 07-06-2022
Public Assessment Report Public Assessment Report English 31-03-2009
Patient Information leaflet Patient Information leaflet French 07-06-2022
Summary of Product characteristics Summary of Product characteristics French 07-06-2022
Public Assessment Report Public Assessment Report French 31-03-2009
Patient Information leaflet Patient Information leaflet Italian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Italian 07-06-2022
Public Assessment Report Public Assessment Report Italian 31-03-2009
Patient Information leaflet Patient Information leaflet Latvian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Latvian 07-06-2022
Public Assessment Report Public Assessment Report Latvian 31-03-2009
Patient Information leaflet Patient Information leaflet Lithuanian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-06-2022
Public Assessment Report Public Assessment Report Lithuanian 31-03-2009
Patient Information leaflet Patient Information leaflet Hungarian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 07-06-2022
Public Assessment Report Public Assessment Report Hungarian 31-03-2009
Patient Information leaflet Patient Information leaflet Maltese 07-06-2022
Summary of Product characteristics Summary of Product characteristics Maltese 07-06-2022
Public Assessment Report Public Assessment Report Maltese 31-03-2009
Patient Information leaflet Patient Information leaflet Dutch 07-06-2022
Summary of Product characteristics Summary of Product characteristics Dutch 07-06-2022
Public Assessment Report Public Assessment Report Dutch 31-03-2009
Patient Information leaflet Patient Information leaflet Polish 07-06-2022
Summary of Product characteristics Summary of Product characteristics Polish 07-06-2022
Public Assessment Report Public Assessment Report Polish 31-03-2009
Patient Information leaflet Patient Information leaflet Portuguese 07-06-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 07-06-2022
Public Assessment Report Public Assessment Report Portuguese 31-03-2009
Patient Information leaflet Patient Information leaflet Romanian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Romanian 07-06-2022
Public Assessment Report Public Assessment Report Romanian 31-03-2009
Patient Information leaflet Patient Information leaflet Slovak 07-06-2022
Summary of Product characteristics Summary of Product characteristics Slovak 07-06-2022
Public Assessment Report Public Assessment Report Slovak 31-03-2009
Patient Information leaflet Patient Information leaflet Slovenian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 07-06-2022
Public Assessment Report Public Assessment Report Slovenian 31-03-2009
Patient Information leaflet Patient Information leaflet Finnish 07-06-2022
Summary of Product characteristics Summary of Product characteristics Finnish 07-06-2022
Public Assessment Report Public Assessment Report Finnish 31-03-2009
Patient Information leaflet Patient Information leaflet Swedish 07-06-2022
Summary of Product characteristics Summary of Product characteristics Swedish 07-06-2022
Public Assessment Report Public Assessment Report Swedish 31-03-2009
Patient Information leaflet Patient Information leaflet Norwegian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 07-06-2022
Patient Information leaflet Patient Information leaflet Icelandic 07-06-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 07-06-2022
Patient Information leaflet Patient Information leaflet Croatian 07-06-2022
Summary of Product characteristics Summary of Product characteristics Croatian 07-06-2022

Search alerts related to this product

Alerts Evista ралоксифен хидрохлорид raloxifene

Evista ралоксифен хидрохлорид raloxifene

View documents history

Documents history Documents history

Evista